Tectonic Therapeutic (TECX) Expected to Announce Quarterly Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Tectonic Therapeutic to post earnings of ($1.11) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 3:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.08. On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Trading Down 2.7%

Tectonic Therapeutic stock opened at $32.40 on Tuesday. Tectonic Therapeutic has a 12 month low of $13.70 and a 12 month high of $36.03. The business’s 50 day simple moving average is $23.34 and its 200 day simple moving average is $20.08. The company has a market cap of $608.47 million, a price-to-earnings ratio of -8.00 and a beta of 3.75.

Wall Street Analyst Weigh In

TECX has been the topic of several research reports. Lifesci Capital upgraded Tectonic Therapeutic to a “strong-buy” rating in a research note on Thursday, February 5th. Truist Financial cut their price target on Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tectonic Therapeutic presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.50.

Insiders Place Their Bets

In other news, insider Marcella K. Ruddy sold 10,000 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider owned 69,747 shares in the company, valued at approximately $2,092,410. This trade represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Peter Mcnamara sold 6,262 shares of Tectonic Therapeutic stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.17, for a total transaction of $188,924.54. Following the sale, the insider directly owned 55,285 shares of the company’s stock, valued at $1,667,948.45. This represents a 10.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 19,561 shares of company stock valued at $566,551 in the last quarter. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of large investors have recently added to or reduced their stakes in TECX. Caitong International Asset Management Co. Ltd lifted its stake in Tectonic Therapeutic by 451.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 3,966 shares of the company’s stock worth $62,000 after purchasing an additional 3,247 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Tectonic Therapeutic during the 2nd quarter valued at about $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Tectonic Therapeutic during the 2nd quarter valued at about $119,000. JPMorgan Chase & Co. raised its holdings in shares of Tectonic Therapeutic by 483.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,548 shares of the company’s stock valued at $130,000 after buying an additional 5,426 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Tectonic Therapeutic during the 4th quarter valued at about $134,000. Hedge funds and other institutional investors own 62.63% of the company’s stock.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.